{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:17:51Z","timestamp":1740122271813,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Clinical Research Plan of SHDC","award":["SHDC 2020CR6005-002"],"award-info":[{"award-number":["SHDC 2020CR6005-002"]}]},{"name":"Shanghai Shenkang Clinical Innovation Project","award":["No.SHDC12020112"],"award-info":[{"award-number":["No.SHDC12020112"]}]},{"DOI":"10.13039\/501100011930","name":"Beijing Medical and Health Foundation","doi-asserted-by":"publisher","award":["No.YWJKJJHKB175B"],"award-info":[{"award-number":["No.YWJKJJHKB175B"]}],"id":[{"id":"10.13039\/501100011930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s11060-022-04062-z","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T17:04:45Z","timestamp":1655917485000},"page":"39-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma"],"prefix":"10.1007","volume":"163","author":[{"given":"Qing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"4062_CR1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008377","author":"LR Schaff","year":"2021","unstructured":"Schaff LR, Grommes C (2021) Primary central nervous system lymphoma. Blood. https:\/\/doi.org\/10.1182\/blood.2020008377","journal-title":"Blood"},{"key":"4062_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","volume":"20","author":"JS Mendez","year":"2018","unstructured":"Mendez JS, Ostrom QT, Gittleman H et al (2018) The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol 20:687\u2013694","journal-title":"Neuro Oncol"},{"key":"4062_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.hoc.2021.09.004","volume":"36","author":"U Chukwueke","year":"2022","unstructured":"Chukwueke U, Grommes C, Nayak L (2022) Primary central nervous system lymphomas. Hematol Oncol Clin North Am 36:147\u2013159","journal-title":"Hematol Oncol Clin North Am"},{"key":"4062_CR4","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.3390\/cancers13205061","volume":"13","author":"M Alcantara","year":"2021","unstructured":"Alcantara M, Fuentealba J, Soussain C (2021) Emerging landscape of immunotherapy for primary central nervous system lymphoma. Cancers (Basel) 13:5061","journal-title":"Cancers (Basel)"},{"key":"4062_CR5","unstructured":"Network. NCC. NCCN clinical practice guidelines in oncology: central nervous system cancers (Version1.2021). Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf. Accessed on 4 Jun 2021"},{"key":"4062_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/ejh.13639","volume":"107","author":"N Sieg","year":"2021","unstructured":"Sieg N, Naendrup JH, G\u00f6del P et al (2021) Treatment patterns and disease course of previously untreated primary central nervous system lymphoma: feasibility of MTX-based regimens in clinical routine. Eur J Haematol 107:202\u2013210","journal-title":"Eur J Haematol"},{"key":"4062_CR7","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1016\/S1470-2045(18)30356-5","volume":"19","author":"M van der Meulen","year":"2018","unstructured":"van der Meulen M, Dirven L, Habets EJJ et al (2018) Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review. Lancet Oncol 19:e407\u2013e418","journal-title":"Lancet Oncol"},{"key":"4062_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11060-019-03257-1","volume":"144","author":"DD Correa","year":"2019","unstructured":"Correa DD, Braun E, Kryza-Lacombe M et al (2019) Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. J Neurooncol 144:553\u2013562","journal-title":"J Neurooncol"},{"key":"4062_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/ajco.13427","volume":"17","author":"WS Yoon","year":"2021","unstructured":"Yoon WS, Park JS, Kim YI et al (2021) High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience. Asia Pac J Clin Oncol 17:123\u2013130","journal-title":"Asia Pac J Clin Oncol"},{"key":"4062_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3892\/ijo.2021.5180","volume":"58","author":"Y Liu","year":"2021","unstructured":"Liu Y, Yao Q, Zhang F (2021) Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review). Int J Oncol 58:371\u2013387","journal-title":"Int J Oncol"},{"key":"4062_CR11","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.6004\/jnccn.2020.7667","volume":"18","author":"M Holdhoff","year":"2020","unstructured":"Holdhoff M, Mrugala MM, Grommes C et al (2020) Challenges in the treatment of newly diagnosed and recurrent primary central nervous system lymphoma. J Natl Compr Canc Netw 18:1571\u20131578","journal-title":"J Natl Compr Canc Netw"},{"key":"4062_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.clml.2020.10.015","volume":"21","author":"D Chihara","year":"2021","unstructured":"Chihara D, Dunleavy K (2021) Primary central nervous system lymphoma: evolving biologic insights and recent therapeutic advances. Clin Lymphoma Myeloma Leuk 21:73\u201379","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4062_CR13","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1212\/WNL.0000000000000314","volume":"82","author":"AJ Ferreri","year":"2014","unstructured":"Ferreri AJ, Ciceri F, Brandes AA et al (2014) MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. Neurology 82:1370\u20131373","journal-title":"Neurology"},{"key":"4062_CR14","doi-asserted-by":"publisher","first-page":"25783","DOI":"10.18632\/oncotarget.8370","volume":"7","author":"L Qian","year":"2016","unstructured":"Qian L, Zhou C, Shen J et al (2016) Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy. Oncotarget 7:25783\u201325790","journal-title":"Oncotarget"},{"key":"4062_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ajh.23812","volume":"89","author":"G Olivier","year":"2014","unstructured":"Olivier G, Clavert A, Lacotte-Thierry L et al (2014) A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial. Am J Hematol 89:1024\u20131029","journal-title":"Am J Hematol"},{"key":"4062_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/jcmm.12252","volume":"18","author":"D Zhao","year":"2014","unstructured":"Zhao D, Qian L, Shen J et al (2014) Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma. J Cell Mol Med 18:1081\u20131086","journal-title":"J Cell Mol Med"},{"key":"4062_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1040-8428(03)00120-3","volume":"49","author":"D Crivellari","year":"2004","unstructured":"Crivellari D, Lombardi D, Spazzapan S et al (2004) New oral drugs in older patients: a review of idarubicin in elderly patients. Crit Rev Oncol Hematol 49:153\u2013163","journal-title":"Crit Rev Oncol Hematol"},{"key":"4062_CR18","first-page":"6525","volume":"50","author":"JM Reid","year":"1990","unstructured":"Reid JM, Pendergrass TW, Krailo MD et al (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res 50:6525\u20136528","journal-title":"Cancer Res"},{"issue":"32","key":"4062_CR19","doi-asserted-by":"publisher","first-page":"53701","DOI":"10.18632\/oncotarget.15899","volume":"8","author":"N Fan","year":"2017","unstructured":"Fan N, Zhang L, Xu X et al (2017) Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma. Oncotarget 8(32):53701\u201353713","journal-title":"Oncotarget"},{"key":"4062_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","volume":"21","author":"AJM Ferreri","year":"2003","unstructured":"Ferreri AJM, Blay J-Y, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266\u2013272","journal-title":"J Clin Oncol"},{"key":"4062_CR21","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036\u20131047","journal-title":"Lancet Oncol"},{"key":"4062_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","volume":"20","author":"JEC Bromberg","year":"2019","unstructured":"Bromberg JEC, Issa S, Bakunina K et al (2019) Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 20:216\u2013228","journal-title":"Lancet Oncol"},{"key":"4062_CR23","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJM Ferreri","year":"2016","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217\u2013e227","journal-title":"Lancet Haematol"},{"key":"4062_CR24","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","volume":"374","author":"AJ Ferreri","year":"2009","unstructured":"Ferreri AJ, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512\u20131520","journal-title":"Lancet"},{"key":"4062_CR25","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","volume":"2","author":"A Omuro","year":"2015","unstructured":"Omuro A, Chinot O, Taillandier L et al (2015) Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2:e251\u2013e259","journal-title":"Lancet Haematol"},{"key":"4062_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00277-021-04745-z","volume":"101","author":"T Brezina","year":"2022","unstructured":"Brezina T, von Dewitz H, Schroeder T et al (2022) First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas-a single-centre experience in 61 patients. Ann Hematol 101:607\u2013616","journal-title":"Ann Hematol"},{"key":"4062_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/NRL.0000000000000328","volume":"26","author":"D Gritsch","year":"2021","unstructured":"Gritsch D, Mrugala MM, Marks LA et al (2021) Is autologous stem cell transplantation a safe and effective alternative to whole brain radiation as consolidation therapy in patients with primary central nervous system lymphoma?: A critically appraised topic. Neurologist 26:137\u2013142","journal-title":"Neurologist"},{"key":"4062_CR28","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.5045\/br.2020.S010","volume":"55","author":"YS Choi","year":"2020","unstructured":"Choi YS (2020) Recent advances in the management of primary central nervous system lymphoma. Blood Res 55:S58-s62","journal-title":"Blood Res"},{"key":"4062_CR29","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.3390\/cancers13122934","volume":"13","author":"S Seidel","year":"2021","unstructured":"Seidel S, Margold M, Kowalski T et al (2021) Patients with primary central nervous system lymphoma not eligible for clinical trials: prognostic factors, treatment and outcome. Cancers (Basel) 13:2934","journal-title":"Cancers (Basel)"},{"key":"4062_CR30","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bjh.15661","volume":"184","author":"CP Fox","year":"2019","unstructured":"Fox CP, Phillips EH, Smith J et al (2019) Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol 184:348\u2013363","journal-title":"Br J Haematol"},{"key":"4062_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40364-021-00282-z","volume":"9","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Ding T, Wang S et al (2021) Current and emerging therapies for primary central nervous system lymphoma. Biomark Res 9:32","journal-title":"Biomark Res"},{"key":"4062_CR32","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.2147\/CMAR.S322467","volume":"13","author":"Q Li","year":"2021","unstructured":"Li Q, Ma J, Ma Y et al (2021) Improvement of outcomes of an escalated high-dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study. Cancer Manag Res 13:6115\u20136122","journal-title":"Cancer Manag Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04062-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T09:11:40Z","timestamp":1685524300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04062-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["4062"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04062-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"24 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest regarding the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}